Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATG-022 · 1 trial · 1 indication
Dose Limiting Toxicity
RP2D= Recommended Phase 2 Dose
| Arm | Type | Description |
|---|---|---|
| ATG-022+pembrolizumab/KEYTRUDA® | EXPERIMENTAL | - |
| ATG-022+pembrolizumab/KEYTRUDA®+CAPOX | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ATG-022 | DRUG | 1.8mg/kg Q3W, every 21 days as one cycle |
| pembrolizumab/KEYTRUDA® | DRUG | 20mg Q3W, every 21 days as one cycle |
| CAPOX | DRUG | Standard Dose level for CAPOX: Capecitabine 1000 mg/m2 PO BID on Day 1-14, Oxaliplatin 130 mg/m2 IV on Day 1, Cycled every 21 days (3 weeks) for 8 cycles. |
Inclusion Criteria: 1. Provision of signed and dated, written informed consent prior to any study-specific procedures, sampling, and analyses. 2. Aged ≥18 years as of the date of consent. 3. Histological or cytological confirmation of gastric cancer or gastroesophageal junction adenocarcinoma with ...
ATG-022 is an investigational small molecule being studied for the treatment of unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma that is Claudin (CLDN) 18.2-positive and HER2-negative. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
ATG-022 targets Claudin (CLDN) 18.2, a protein expressed on certain tumor cells. The drug is being evaluated in patients whose tumors are CLDN 18.2-positive and HER2-negative, indicating a biomarker-selected approach to treatment for gastric or gastroesophageal junction adenocarcinoma.
ATG-022 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 1 clinical trials and has not yet received regulatory approval.
ATG-022 is in Phase 1 clinical development. It is being studied in an active Phase Ib/II trial, but the drug remains investigational and has not been approved by the FDA or other regulatory agencies for any use.
ATG-022 is being evaluated in a Phase Ib/II study with the identifier NCT07327229. This trial is recruiting participants in China and is studying ATG-022 in combination with pembrolizumab, with or without chemotherapy, in patients with CLDN 18.2-positive, HER2-negative unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
No, ATG-022 is not the same as pembrolizumab. ATG-022 is a small molecule targeting CLDN 18.2, while pembrolizumab is a separate immunotherapy agent. In the ongoing clinical trial, ATG-022 is being studied in combination with pembrolizumab, with or without chemotherapy, for the treatment of gastric cancer.